TY - JOUR
T1 - Pre-natal manifestation of systemic developmental abnormalities in spinal muscular atrophy
AU - Motyl, Anna A. L.
AU - Faller, Kiterie M. E.
AU - Groen, Ewout J. N.
AU - Kline, Rachel A.
AU - Eaton, Samantha L.
AU - Ledahawsky, Leire M.
AU - Chaytow, Helena
AU - Lamont, Douglas J.
AU - Wishart, Thomas M.
AU - Huang, Yu-Ting
AU - Gillingwater, Thomas H.
N1 - © The Author(s) 2020. Published by Oxford University Press.
PY - 2020/8/15
Y1 - 2020/8/15
N2 - Spinal muscular atrophy (SMA) is a neuromuscular disease caused by mutations in survival motor neuron 1 (SMN1). SMN-restoring therapies have recently emerged; however, pre-clinical and clinical studies revealed a limited therapeutic time-window and systemic aspects of the disease. This raises a fundamental question of whether SMA has pre-symptomatic, developmental components to disease pathogenesis. We have addressed this by combining micro-computed tomography (μCT) and comparative proteomics to examine systemic pre-symptomatic changes in a prenatal mouse model of SMA. Quantitative μCT analyses revealed that SMA embryos were significantly smaller than littermate controls, indicative of general developmental delay. More specifically, cardiac ventricles were smaller in SMA hearts, whilst liver and brain remained unaffected. In order to explore the molecular consequences of SMN depletion during development, we generated comprehensive, high-resolution, proteomic profiles of neuronal and non-neuronal organs in SMA mouse embryos. Significant molecular perturbations were observed in all organs examined, highlighting tissue-specific prenatal molecular phenotypes in SMA. Together, our data demonstrate considerable systemic changes at an early, pre-symptomatic stage in SMA mice, revealing a significant developmental component to SMA pathogenesis.
AB - Spinal muscular atrophy (SMA) is a neuromuscular disease caused by mutations in survival motor neuron 1 (SMN1). SMN-restoring therapies have recently emerged; however, pre-clinical and clinical studies revealed a limited therapeutic time-window and systemic aspects of the disease. This raises a fundamental question of whether SMA has pre-symptomatic, developmental components to disease pathogenesis. We have addressed this by combining micro-computed tomography (μCT) and comparative proteomics to examine systemic pre-symptomatic changes in a prenatal mouse model of SMA. Quantitative μCT analyses revealed that SMA embryos were significantly smaller than littermate controls, indicative of general developmental delay. More specifically, cardiac ventricles were smaller in SMA hearts, whilst liver and brain remained unaffected. In order to explore the molecular consequences of SMN depletion during development, we generated comprehensive, high-resolution, proteomic profiles of neuronal and non-neuronal organs in SMA mouse embryos. Significant molecular perturbations were observed in all organs examined, highlighting tissue-specific prenatal molecular phenotypes in SMA. Together, our data demonstrate considerable systemic changes at an early, pre-symptomatic stage in SMA mice, revealing a significant developmental component to SMA pathogenesis.
UR - http://www.scopus.com/inward/record.url?scp=85090782581&partnerID=8YFLogxK
U2 - 10.1093/hmg/ddaa146
DO - 10.1093/hmg/ddaa146
M3 - Article
C2 - 32644120
SN - 0964-6906
VL - 29
SP - 2674
EP - 2683
JO - Human Molecular Genetics
JF - Human Molecular Genetics
IS - 16
ER -